Naomi Haas, MD

Articles by Naomi Haas, MD

KEYNOTE-564: 5-Year Follow-Up Results

Naomi Haas, MDAdvanced Renal Cell Carcinoma | June 4, 2025

Dr. Haas provides an update on a 5-year follow-up of KEYNOTE-564 and the survival benefits of adjuvant pembrolizumab for RCC.